Associations Between Hyperactive Neuropsychiatric Symptoms and Brain Morphology in Mild Cognitive Impairment and Alzheimer's Disease

被引:0
|
作者
El Haffaf, Lyna Mariam [1 ,2 ]
Ronat, Lucas [1 ,3 ]
Cannizzaro, Adriana [1 ,2 ]
Hanganu, Alexandru [1 ,2 ]
机构
[1] Inst Univ Geriatrie Montreal, CIUSSS Ctr Sud Ile Montreal, Ctr Rech, Montreal, PQ, Canada
[2] Univ Montreal, Fac Arts & Sci, Dept Psychol, Montreal, PQ, Canada
[3] Univ Montreal, Fac Med, Dept Med, Montreal, PQ, Canada
关键词
Agitation; Alzheimer's disease; cognitively normal older adults; cortical structures; disinhibition; irritability; magnetic resonance imaging; mild cognitive impairment; neuropsychiatric symptoms; CORTICAL SURFACE-AREA; DISINHIBITION; ATROPHY; CORTEX; PREVALENCE; THICKNESS; DEMENTIA; VOLUME;
D O I
10.3233/JAD-220857
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Background: Hyperactive neuropsychiatric symptoms (NPS) (i.e., agitation, disinhibition, and irritability) are among the most challenging symptoms to manage in Alzheimer's disease (AD). However, their underlying brain correlates have been poorly studied. Objective: We aimed to investigate the associations between the total score of hyperactive NPS and brain structures in participants with AD, mild cognitive impairment (MCI), and cognitively normal older adults (CN). Methods: Neuropsychiatric and 3T MRI data from 216 AD, 564 MCI, and 660 CN participants were extracted from the Alzheimer's Disease Neuroimaging Initiative database. To define NPS and brain structures' associations, we fitted a general linear model (GLM) in two ways: 1) an overall GLM including all three groups (AD, MCI, CN) and 2) three pair-wise GLMs (AD versus MCI, MCI versus CN, AD versus CN). The cortical changes as a function of NPS total score were investigated using multiple regression analyses. Results: Results from the overall GLM include associations between 1) agitation and the right parietal supramarginal surface area in the MCI-CN contrast, 2) disinhibition and the cortical thickness of the right frontal pars opercularis and temporal inferior in the AD-MCI contrast, and 3) irritability and the right frontal pars opercularis, frontal superior, and temporal superior volumes in the MCI-CN contrast. Conclusions: Our study shows that each hyperactive NPS is associated with distinct brain regions in AD, MCI, and CN (groups with different levels of cognitive performance). This suggests that each NPS is associated with a unique signature of brain morphology, including variations in volume, thickness, or area.
引用
收藏
页码:841 / 853
页数:13
相关论文
共 50 条
  • [11] Occurrence of neuropsychiatric symptoms and psychiatric disorders in mild Alzheimer's disease and mild cognitive impairment subtypes
    Di Iulio, Fulvia
    Palmer, Katie
    Blundo, Carlo
    Casini, Anna Rosa
    Gianni, Walter
    Caltagirone, Carlo
    Spalletta, Gianfranco
    INTERNATIONAL PSYCHOGERIATRICS, 2010, 22 (04) : 629 - 640
  • [12] Neuropsychiatric Symptoms and Risk of Progression to Alzheimer's Disease Among Mild Cognitive Impairment Subjects
    Dietlin, Simon
    Soto, Maria
    Kiyasova, Vera
    Pueyo, Maria
    de Mauleon, Adelaide
    Delrieu, Julien
    Ousset, Pierre Jean
    Vellas, Bruno
    JOURNAL OF ALZHEIMERS DISEASE, 2019, 70 (01) : 25 - 34
  • [13] Comorbidities in mild cognitive impairment due to Alzheimer's disease: Effects on neuropsychiatric symptoms and therapy
    Menegon, Federico
    Tondo, Giacomo
    De Marchi, Fabiola
    Aprile, Davide
    Serra, Paola
    Sarasso, Barbara
    Comi, Cristoforo
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2023, 455
  • [14] CEREBROSPINAL FLUID CORRELATES OF NEUROPSYCHIATRIC SYMPTOMS IN PATIENTS WITH ALZHEIMER'S DISEASE/MILD COGNITIVE IMPAIRMENT
    Showraki, Alireza
    Murari, Geetanjali
    Ismail, Zahinoor
    Barfett, Joseph
    Munoz, David
    Schweizer, Tom
    Fornazzari, Luis
    Fischer, Corinne
    AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, 2019, 27 (03): : S88 - S89
  • [15] Neuropsychiatric Symptoms in Parkinson's Disease with and without Mild Cognitive Impairment
    Bocanegra, Y.
    Baena, A.
    Carmona, J.
    Aguirre, D. C.
    Pineda, D.
    Buritica, O.
    Quiroz, Y.
    Lopera, F.
    ARCHIVES OF CLINICAL NEUROPSYCHOLOGY, 2019, 34 (07) : 1238 - 1238
  • [16] Neuropsychiatric Symptoms in Parkinson's Disease with Mild Cognitive Impairment and Dementia
    Leroi, Iracema
    Pantula, Hiranmayi
    McDonald, Kathryn
    Harbishettar, Vijay
    PARKINSONS DISEASE, 2012, 2012
  • [17] Myelin content changes in probable Alzheimer's disease and mild cognitive impairment: Associations with age and severity of neuropsychiatric impairment
    Kavroulakis, Eleftherios
    Simos, Panagiotis G.
    Kalaitzakis, Georgios
    Maris, Thomas G.
    Karageorgou, Dimitra
    Zaganas, Ioannis
    Panagiotakis, Simeon
    Basta, Maria
    Vgontzas, Alexandros
    Papadaki, Efrosini
    JOURNAL OF MAGNETIC RESONANCE IMAGING, 2018, 47 (05) : 1359 - 1372
  • [18] Frequency and subgroups of neuropsychiatric symptoms in mild cognitive impairment and different stages of dementia in Alzheimer's disease
    Siafarikas, N.
    Selbaek, G.
    Fladby, T.
    Benth, J. Saltyte
    Auning, E.
    Aarsland, D.
    INTERNATIONAL PSYCHOGERIATRICS, 2018, 30 (01) : 103 - 113
  • [19] Frequency and severity of neuropsychiatric symptoms in Alzheimer's disease and mild cognitive impairment: Influence of the APOE genotype
    Alvarez, XA
    Laredo, M
    Couceiro, V
    Sampedro, C
    Cacabelos, R
    Illescas, E
    Vargas, M
    Moessler, H
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2004, 7 : S384 - S384
  • [20] Purinergic signaling in cognitive impairment and neuropsychiatric symptoms of Alzheimer's disease
    Ribeiro, Deidiane Elisa
    Petiz, Lyvia Lintzmaier
    Glaser, Talita
    Oliveira-Giacomelli, Agatha
    Andrejew, Roberta
    Saab, Fernando de Azevedo Ribeiro
    Milanis, Milena da Silva
    Campos, Henrique Correia
    Sampaio, Vanessa Fernandes Arnaud
    La Banca, Sophia
    Longo, Beatriz Monteiro
    Lameu, Claudiana
    Tang, Yong
    Resende, Rodrigo Ribeiro
    Ferreira, Sergio T.
    Ulrich, Henning
    NEUROPHARMACOLOGY, 2023, 226